Logo image of KPTI

KARYOPHARM THERAPEUTICS INC (KPTI) Stock Fundamental Analysis

USA - NASDAQ:KPTI - US48576U2050 - Common Stock

6.26 USD
0 (0%)
Last: 9/16/2025, 8:00:02 PM
6.26 USD
0 (0%)
After Hours: 9/16/2025, 8:00:02 PM
Fundamental Rating

1

Taking everything into account, KPTI scores 1 out of 10 in our fundamental rating. KPTI was compared to 540 industry peers in the Biotechnology industry. KPTI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, KPTI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KPTI has reported negative net income.
KPTI had a negative operating cash flow in the past year.
KPTI had negative earnings in each of the past 5 years.
In the past 5 years KPTI always reported negative operating cash flow.
KPTI Yearly Net Income VS EBIT VS OCF VS FCFKPTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -117.82%, KPTI is not doing good in the industry: 79.07% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -117.82%
ROE N/A
ROIC N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KPTI Yearly ROA, ROE, ROICKPTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

With an excellent Gross Margin value of 96.37%, KPTI belongs to the best of the industry, outperforming 95.56% of the companies in the same industry.
KPTI's Gross Margin has been stable in the last couple of years.
KPTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
KPTI Yearly Profit, Operating, Gross MarginsKPTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

0

2. Health

2.1 Basic Checks

KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KPTI has more shares outstanding
The number of shares outstanding for KPTI has been increased compared to 5 years ago.
KPTI has a worse debt/assets ratio than last year.
KPTI Yearly Shares OutstandingKPTI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
KPTI Yearly Total Debt VS Total AssetsKPTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

KPTI has an Altman-Z score of -23.92. This is a bad value and indicates that KPTI is not financially healthy and even has some risk of bankruptcy.
KPTI's Altman-Z score of -23.92 is on the low side compared to the rest of the industry. KPTI is outperformed by 86.11% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.92
ROIC/WACCN/A
WACC6.55%
KPTI Yearly LT Debt VS Equity VS FCFKPTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

KPTI has a Current Ratio of 0.99. This is a bad value and indicates that KPTI is not financially healthy enough and could expect problems in meeting its short term obligations.
KPTI has a Current ratio of 0.99. This is amonst the worse of the industry: KPTI underperforms 87.59% of its industry peers.
A Quick Ratio of 0.94 indicates that KPTI may have some problems paying its short term obligations.
KPTI's Quick ratio of 0.94 is on the low side compared to the rest of the industry. KPTI is outperformed by 87.41% of its industry peers.
Industry RankSector Rank
Current Ratio 0.99
Quick Ratio 0.94
KPTI Yearly Current Assets VS Current LiabilitesKPTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

KPTI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.19%.
Looking at the last year, KPTI shows a decrease in Revenue. The Revenue has decreased by -5.76% in the last year.
The Revenue has been growing by 28.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292%
Revenue 1Y (TTM)-5.76%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-11.35%

3.2 Future

KPTI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.22% yearly.
The Revenue is expected to grow by 23.98% on average over the next years. This is a very strong growth
EPS Next Y-10.84%
EPS Next 2Y13.12%
EPS Next 3Y19.09%
EPS Next 5Y15.22%
Revenue Next Year-1.57%
Revenue Next 2Y3.91%
Revenue Next 3Y13.18%
Revenue Next 5Y23.98%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
KPTI Yearly Revenue VS EstimatesKPTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
KPTI Yearly EPS VS EstimatesKPTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KPTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KPTI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KPTI Price Earnings VS Forward Price EarningsKPTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KPTI Per share dataKPTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

KPTI's earnings are expected to grow with 19.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.12%
EPS Next 3Y19.09%

More info and screens

0

5. Dividend

5.1 Amount

KPTI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KARYOPHARM THERAPEUTICS INC

NASDAQ:KPTI (9/16/2025, 8:00:02 PM)

After market: 6.26 0 (0%)

6.26

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners42.85%
Inst Owner Change-34.88%
Ins Owners1.1%
Ins Owner Change-0.01%
Market Cap54.27M
Analysts81.54
Price Target17.95 (186.74%)
Short Float %26.87%
Short Ratio11.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.85%
Min EPS beat(2)-3.34%
Max EPS beat(2)35.04%
EPS beat(4)3
Avg EPS beat(4)11.18%
Min EPS beat(4)-3.34%
Max EPS beat(4)35.04%
EPS beat(8)5
Avg EPS beat(8)22.63%
EPS beat(12)8
Avg EPS beat(12)18.39%
EPS beat(16)11
Avg EPS beat(16)26.83%
Revenue beat(2)1
Avg Revenue beat(2)-7.91%
Min Revenue beat(2)-16.5%
Max Revenue beat(2)0.68%
Revenue beat(4)2
Avg Revenue beat(4)-7.33%
Min Revenue beat(4)-16.5%
Max Revenue beat(4)0.68%
Revenue beat(8)3
Avg Revenue beat(8)-3.88%
Revenue beat(12)6
Avg Revenue beat(12)-2.41%
Revenue beat(16)10
Avg Revenue beat(16)16.85%
PT rev (1m)-18.52%
PT rev (3m)-52.75%
EPS NQ rev (1m)2.92%
EPS NQ rev (3m)3.94%
EPS NY rev (1m)10.37%
EPS NY rev (3m)23.85%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)3.1%
Revenue NY rev (1m)1.19%
Revenue NY rev (3m)1.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.4
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.59
EYN/A
EPS(NY)-7.24
Fwd EYN/A
FCF(TTM)-11.87
FCFYN/A
OCF(TTM)-11.87
OCFYN/A
SpS15.83
BVpS-27.56
TBVpS-27.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -117.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.37%
FCFM N/A
ROA(3y)-50.71%
ROA(5y)-51.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.86%
GM growth 5Y0.37%
F-Score3
Asset Turnover1.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.56%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.99
Quick Ratio 0.94
Altman-Z -23.92
F-Score3
WACC6.55%
ROIC/WACCN/A
Cap/Depr(3y)20.37%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-292%
EPS Next Y-10.84%
EPS Next 2Y13.12%
EPS Next 3Y19.09%
EPS Next 5Y15.22%
Revenue 1Y (TTM)-5.76%
Revenue growth 3Y-11.54%
Revenue growth 5Y28.85%
Sales Q2Q%-11.35%
Revenue Next Year-1.57%
Revenue Next 2Y3.91%
Revenue Next 3Y13.18%
Revenue Next 5Y23.98%
EBIT growth 1Y12.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.13%
OCF growth 3YN/A
OCF growth 5YN/A